GLP-1 Receptor Agonist
The Semaglutide File
FDA Approved (Ozempic, Wegovy, Rybelsus) · Novo Nordisk
Strong Evidence
The most widely prescribed GLP-1 drug. FDA-approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy).
Mechanism
GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glycemic control
Key Data
weight Loss
~15% body weight (STEP trials)
approval Status
FDA approved 2021 (Wegovy for weight loss)
brand Names
- · Ozempic
- · Wegovy
- · Rybelsus
common Side Effects
- · Nausea
- · Vomiting
- · Diarrhea
- · Constipation
Full Article Coming Soon
The full The Semaglutide File will cover mechanism of action, clinical trial evidence, dosage data, side effects, comparisons, and FAQs — all evidence-rated and referenced. Check back soon.
This content is for informational purposes only. Not medical advice. Always consult a qualified healthcare provider before making any health decisions.